Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
- Written by: ACN Newswire - Press Releases
Read more //?#
.
-at-esmo-virtual-congress-2020&media=https://www.businessdailymedia.com/http://www.acnnewswire.com/images/company/Eisai.jpg&description=Eisai%20Presents%20Latest%20Data%20of%20Phase%20I%20Clinical%20Trial%20on%20Liposomal%20Formulation%20of%20Anti-Cancer%20Agent%20Halaven%20(Eribulin)%20at%20ESMO%20Virtual%20Congress%202020 "Pin It")
Click Frenzy returns with a free EOFY sale event for retailers this month
New owners Gabby and Hezi Leibovich bring back Australia’s leading ecommerce sales event with Australia Post as Major Sponsor Click Frenzy is ...
The 95 Per Cent Failure Rate Is Not An AI Problem
Most Australian SMEs I speak with are already having a go at AI. Some are running formal pilots, others have a team member quietly experimenting o...
New AR tech helping to solve field service skills crisis
AI-enabled augmented reality (AR) smart glasses are emerging as a new practical solution to fill a shortage of field service technicians maintaini...
For Midsize Companies, Global Payroll Systems Matter More to Business-Security Than You Think
When a midsize company expands across borders, its payroll operation becomes exponentially more complex. These organisations typically face a new ...
GEO and the AI search shift reshaping Australian and New Zealand business visibility
For years, one of the biggest digital marketing questions for businesses was ‘how do we get onto page one of Google?’ That question still matters, ...
Why self-service is reshaping fleet management for modern businesses
Fleet management today is constrained by fragmented systems and heavy administrative demands. A lot of the work still relies on booking vehicles and...